Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

COPENHAGEN (Reuters) -Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent.